Market Place
Sourcing Support
ORYZON Reports Q3 2024 Financial Results And Update
24 Oct 2024 //
GLOBENEWSWIRE
Oryzon Presents Final PORTICO Vafidemstat BPD Trial Data
23 Sep 2024 //
GLOBENEWSWIRE
ORYZON Receives Patent Intent For Vafidemstat In Borderline Personality
11 Sep 2024 //
GLOBENEWSWIRE
ORYZON Strengthens Patent Portfolio for Vafidemstat with New Grant
03 Sep 2024 //
GLOBENEWSWIRE
ORYZON To Receive Two Important Patents For Vafidemstat In Japan
08 Jul 2024 //
GLOBENEWSWIRE
ORYZON Present of Final Data From Vafidemstat’s Global Phase IIb Trial
26 Jun 2024 //
GLOBENEWSWIRE
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
22 Apr 2024 //
GLOBENEWSWIRE
ORYZON to Host KOL Event on PIIb PORTICO Topline Study Results of Vafidemstat
19 Jan 2024 //
GLOBENEWSWIRE
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat
05 Jan 2024 //
GLOBENEWSWIRE
ORYZON presents safety data from vafidemstat™s ongoing Phase IIb trial
10 Oct 2023 //
GLOBENEWSWIRE
Oryzon Announces Completed Patient Recruitment in Ph IIb Trial of vafidemstat
26 Jul 2023 //
GLOBENEWSWIRE
ORYZON Bags Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial
04 Jan 2022 //
GLOBENEWSWIRE
ORYZON Enrolls First Patient in EVOLUTION, a Phase IIb Clinical Trial
17 Nov 2021 //
GLOBENEWSWIRE
ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial
18 Oct 2021 //
GLOBENEWSWIRE
ORYZON Presents vafidemstat 12-month Data From its Phase IIa Clinical Trials
09 Mar 2021 //
GLOBENEWSWIRE
ORYZON Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat
10 Nov 2020 //
GLOBENEWSWIRE
ORYZON to Initiate ESCAPE:a Ph II Clinical Trial to Test Efficacy of Vafidemstat
24 Apr 2020 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.